
Cadila Healthcare Limited has informed the Exchange regarding a press release dated July 21, 2021, titled "Zydus Cadila receives tentative approval from the USFDA for Ibrutinib Tablets".
Filed with NSE ·

Cadila Healthcare Limited has informed the Exchange regarding a press release dated July 21, 2021, titled "Zydus Cadila receives tentative approval from the USFDA for Ibrutinib Tablets".
6ix hasn’t read this filing yet.
Zydus Lifesciences Limited on 6ix
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences